export default function HereditaryCancerPanel() { const features = [ { title: "Comprehensive Gene Coverage", desc: "Includes high- and moderate-risk genes such as BRCA1, BRCA2, TP53, MLH1, MSH2, APC, and others." }, { title: "Germline Variant Detection", desc: "Accurately detects SNVs, Indels, and selected CNVs in genes associated with inherited cancer risk." }, { title: "Family-Centered Testing", desc: "Supports cascade testing for at-risk relatives, enabling early detection and prevention." }, { title: "Clinical Actionability", desc: "Provides insights that guide surveillance, preventive measures, and personalized treatment planning." }, { title: "High Sensitivity & Specificity", desc: "Uses ≥100X sequencing depth with ≥90% Q30 base quality for reliable variant calling." }, { title: "Expert Interpretation & Reporting", desc: "Variants classified using ACMG guidelines, backed by curated literature and clinical databases." }, { title: "Genetic Counseling Support", desc: "Optional access to pre- and post-test counseling for patient education and informed decision-making." } ]; const points = [ "About 5-10% of all cancers are linked to inherited genetic mutations, often going undetected until late stages or after multiple family members are affected.", "The Operify Hereditary Cancer Panel screens key high- and moderate-risk genes associated with hereditary cancer syndromes like HBOC, Lynch Syndrome (LS), Li Fraumeni Syndrome (LFS), Familial Adenomatous Polyposis (FAP), Cowden Syndrome (CS), Peutz-Jeghers Syndrome (PJS), Neurofibromatosis (NF) etc.", "Early identification of germline mutations enables proactive clinical decisions, including risk-reducing strategies, targeted surveillance, and family cascade testing.", "Studies show that genetic testing in hereditary cancer cases improves outcomes and informs care for both patients and at-risk relatives." ]; return (

Operify Hereditary Cancer Panel

Key Features

{features.map((feature, idx) => ( ))}
Feature Description
{feature.title} {feature.desc}
); }